Sign In  |  Register  |  About San Rafael  |  Contact Us

San Rafael, CA
September 01, 2020 1:37pm
7-Day Forecast | Traffic

  • Search Hotels in San Rafael

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

105.06 +2.43 (+2.37%)
Official Closing Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S ADR

< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
65 66 Next >
Move Over, Tesla! These 6 Stocks Could Replace It in the "Magnificent 7"
Tesla is failing to keep pace with the rest of the Magnificent Seven. 
Via The Motley Fool
Should Pfizer Acquire Viking Therapeutics to Take on Eli Lilly and Novo Nordisk in the Obesity Drug Market?
Viking Therapeutics just might be an attractive acquisition target for Pfizer. 
Via The Motley Fool
3 Pharma Stocks to Sell in March Before They Crash & Burn
Discover top pharma stocks to sell in March before they plummet. Learn why ACAD, AMLX and WST are on the list for urgent sell-off decisions. 
Via InvestorPlace
Smart Money Is Betting Big In NVO Options
Via Benzinga
Is WW Stock on the Brink of Bankruptcy?
It's hard to see what WW, the company formerly called Weight Watchers, can do now that Oprah Winfrey has turned against it. 
Via InvestorPlace
Top 7 Biotech Winners Of Novo Nordisk, Eli Lilly's Outsourcing Strategy For Weight-Loss Drugs: Goldman Sachs
Goldman Sachs analysts identified a substantial opportunity in the manufacturing sector for new obesity therapeutics, as demand for these treatments escalates. 
Via Benzinga
Eli Lilly Taps Amazon's Pharmacy To Deliver Meds, Including Weight-Loss Drug Zepbound
The company is bolstering the ways it delivers medicines through its new LillyDirect website. 
Via Investor's Business Daily
Pharmaceutical Crime Jumps 50% As Criminals Seek To Capitalize Rising Tide of Counterfeit Weight-Loss Drugs
Combatting counterfeit weight-loss drugs: Insights into the surge, global impact, and efforts by pharmaceutical giants like Novo Nordisk and Eli Lilly to protect consumers. 
Via Benzinga
Can WeightWatchers Regain its Mojo after Oprah Steps Down?
WW International Inc. (NASDAQ: WW) (WeightWatchers) has had a disastrous 2024, with its shares collapsing 66.7% year-to-date (YTD). 
Via MarketBeat
Why Novo Nordisk Stock Was a Winner Today
A team of analysts believes the popular company has excellent potential for future growth. 
Via The Motley Fool
Newly Listed Obesity Player Fractyl Health Shares Encouraging Preclinical Data
Fractyl Health unveils RJVA-001, a groundbreaking GLP-1 gene therapy for metabolic diseases. Promising preclinical results show durable blood sugar and weight reduction in diabetes mouse model. 
Via Benzinga
1 Big New Reason to Buy Novo Nordisk Stock Hand Over Fist Right This Instant
The pharma giant could have yet another knockout obesity drug on the way. 
Via The Motley Fool
US Health Agency Reviews Novo Nordisk's Wegovy For Potential Use In Treating Heart Disease Patients With Obesity
The CMS is reviewing the FDA's action to expand use of Wegovy to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or... 
Via Benzinga
Exposures Product Safety
Gary Black Keeping Tabs On Oprah's Upcoming TV Special About Ozempic — 'Shame, Blame And The Weight Loss Revolution'
Future Fund co-founder Gary Black shared details about Oprah Winfrey's upcoming TV special discussing her weight loss journey and the use of GLP-1 weight loss drugs, potentially impacting stocks of... 
Via Benzinga
On the Dip: 3 Stocks to Snatch Up Whenever the Market Stumbles
Build a solid portfolio with stocks that shine through all seasons. Here are the stocks to buy the dip each time the market stumbles. 
Via InvestorPlace
Anti-Counterfeiting Group Identifies Fake Diabetes Drug Ozempic in 16 Countries: Sparks Patient Harm Concerns
Novo Nordisk tackles global counterfeit drug crisis with CEO Lars Fruergaard Jorgensen. Insights on patient safety, supply challenges, and FDA actions. 
Via Benzinga
Exposures Product Safety
Top Wall Street Analysts Flag US Market Concentration Anxiety, Advise Investors To Adopt 'Barbell Approach'
Goldman Sachs urges investors to diversify geographically due to high concentration in US tech stocks, with Japan, healthcare, and European GRANOLAS highlighted as promising markets. 
Via Benzinga
Obesity Drugs 2024: The Skinny on the Top 3 Weight-Loss Stocks
With therapeutics focused on slimming down skyrocketing, it’s time to consider these top weight-loss stocks. 
Via InvestorPlace
Forget Tesla: I Think This Stock Should Replace It in the "Magnificent Seven"
Tesla doesn't look very magnificent these days. But there's another stock that does. 
Via The Motley Fool
Is Novo Nordisk a Buy After Its New Obesity Candidate's Success in a Clinical Trial?
Encouraging results recently pushed the pharma stock up to new heights. 
Via The Motley Fool
Pharma Stock Roundup: Novo Nordisk's New Obesity Pill Data, Roche, AstraZeneca's Pipeline Updates
This week, data from Novo Nordisk’s early-stage study on a new weight loss pill called amycretin showed that it could be more effective than Wegovy. Meanwhile, the FDA approved Johnson & Johnson's lung... 
Via Talk Markets
Exposures Product Safety
The Top 3 Pharma Stocks to Buy in March2024
Investors explore the top three biotechnology stocks to buy in 2024 which are leading the anti-obesity market surge. 
Via InvestorPlace
Oprah Winfrey To Spotlight Weight Loss Drugs In New TV Special: Will 'Shame, Blame' Come To Drug Companies — Or Could They Get Another Lift?
Weight loss drugs could get an increased spotlight with a television special from legendary TV host Oprah Winfrey. 
Via Benzinga
Novo Nordisk's Game-Changer: FDA Approves Weight Loss Sensation Wegovy For Heart Health, Potential Insurance Coverage
Novo Nordisk's Wegovy receives FDA approval for expanded use, targeting a significant reduction in cardiovascular events and weight management. 
Via Benzinga
Exposures Product Safety
Novo Nordisk Wins FDA Approval For Obesity Drug, Wegovy, To Cut Cardiovascular Risk
Novo Nordisk stock slumped despite winning FDA approval for its Wegovy in reducing cardiovascular risks. 
Via Investor's Business Daily
Exposures Product Safety
3 Stock Winners That Are Up 1,000% or More in 2024
Dig deep enough, and find a story hot enough, and you can uncover potential stock winners up 1,000%. Here are three. 
Via InvestorPlace
Novo Nordisk Sets Timeframe For Its Next-Gen Experimental Obesity Drug
"Novo Nordisk's optimism soars with promising early trial data for amycretin, an experimental weight loss pill. Expect significant weight loss and cardiovascular benefits. Phase 2 trial begins in late... 
Via Benzinga
Stock Market Rally Hits Fresh Highs As Nvidia, Novo Nordisk, Bitcoin Soar: Weekly Review
The Nasdaq and S&P 500 hit new all-time highs. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Are These 5 Undervalued Stocks Ready to Break Out?
Undervalued stocks Albemarle, Ionis, Insulet, Hess and Wynn beat earnings views, offering potential for investors to buy quality companies at discounted prices. 
Via MarketBeat
Retail Traders Ditch Tesla, Apple, Google For Pharma Stocks Like Ozempic-Maker Novo Nordisk And Eli Lilly: JPMorgan
Retail traders have been observed to be selling off their shares in the 'Magnificent Seven' tech stocks, with a noticeable shift towards pharmaceutical stocks, according to a recent report by... 
Via Benzinga
< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
65 66 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanRafael.com & California Media Partners, LLC. All rights reserved.